305 related articles for article (PubMed ID: 24450632)
1. PARP inhibitors for anticancer therapy.
Curtin N
Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Drew Y; Plummer R
Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
9. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
10. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
Curtin NJ; Szabo C
Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
13. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
14. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
O'Sullivan Coyne G; Chen AP; Meehan R; Doroshow JH
Drugs; 2017 Feb; 77(2):113-130. PubMed ID: 28078645
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
18. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
19. The role of PARP in DNA repair and its therapeutic exploitation.
Javle M; Curtin NJ
Br J Cancer; 2011 Oct; 105(8):1114-22. PubMed ID: 21989215
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
